Skip to main content
    I

    Integra LifeSciences Holdings (IART)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $13.98
    -0.42 (-2.92%)

    Market Cap: $1.12B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Integra LifeSciences Holdings (IART) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Integra LifeSciences Holdings (IART) to earn $2.34 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.64B. Of 12 analysts, 3 rate the stock Buy or Strong Buy, 7 Hold and 2 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 25% of the ratings.

    RatingAnalystsShare
    Strong Buy18.3%
    Buy216.7%
    Hold758.3%
    Sell00.0%
    Strong Sell216.7%
    Consensus
    Hold
    Total analysts
    12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 1.3% and revenue estimates rise 1.8%.

    Fiscal year ending Dec 31, 2026
    $2.34
    EPS consensus, revenue $1.64B
    Fiscal year ending Dec 31, 2027
    $2.37
    EPS consensus, revenue $1.67B
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.34$2.31 to $2.3512$1.64B$1.64B to $1.65B11
    Dec 31, 2027$2.37$2.30 to $2.4512$1.67B$1.65B to $1.70B11

    Quarterly Estimates

    The EPS consensus falls from $0.68 for the quarter ending Dec 31, 2026 to $0.49 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.68$0.61 to $0.8813$430.84M$411.70M to $445.20M13
    Mar 31, 2027$0.49$0.41 to $0.608$388.16M$383.71M to $395.12M6

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 16 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202605
    Fiscal year ending Dec 31, 2027011

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 4.9% from $2.46.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$2.34$2.33$2.41$2.46$2.46-4.9%
    Fiscal year ending Dec 31, 2027$2.37$2.39$2.60$2.61$2.61-9.0%
    Quarter ending Mar 31, 2027$0.49$0.49$0.54$0.54$0.54-7.8%

    Frequently Asked Questions About IART

    What is the IART stock forecast?

    Consensus analyst estimates put Integra LifeSciences Holdings's EPS at $2.34 for the fiscal year ending Dec 31, 2026, on revenue of $1.64B. The consensus rating from 12 analysts is Hold.

    How do analysts rate IART stock?

    Of 12 analysts covering Integra LifeSciences Holdings, 1 rates it Strong Buy, 2 Buy, 7 Hold, 0 Sell and 2 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from IART next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.34, with estimates from $2.31 to $2.35 from 12 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.37, with estimates from $2.30 to $2.45 from 12 analysts.

    What revenue do analysts expect from Integra LifeSciences Holdings next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.64B, with estimates from $1.64B to $1.65B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.67B, with estimates from $1.65B to $1.70B.

    How many analysts cover IART?

    12 analysts rate Integra LifeSciences Holdings stock, and 12 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.